Phaseline

Companies › AgelessRx

AgelessRx: clinical trials, targets and expected readouts

4 active drug programs in 21 registered trials: 9 Phase 2, 7 Phase 3, 3 Phase 4, 2 Phase 1; Other, Neurology, Infectious disease, Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Glutathione (GSH)
Antioxidant
–Phase 3Healthspan Improvement; Renal Failure–
NAD+ (nicotinamide adenine dinucleotide)
NAD+ biosynthesis precursor/cofactor
–Phase 3Healthspan Improvement–
Naltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug …–
Sirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Healthspan Improvement; Longevity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07092618SirolimusPhase 2LongevityOtherAug 2025
NCT07092618NaltrexonePhase 2LongevityOtherAug 2025
NCT07475546SirolimusPhase 3Healthspan ImprovementOtherApr 2026
NCT07475546NaltrexonePhase 3Healthspan ImprovementOtherApr 2026
NCT07475546NAD+ (nicotinamide adenine dinucleotide)Phase 3Healthspan ImprovementOtherApr 2026
NCT07475546Glutathione (GSH)Phase 3Healthspan ImprovementOtherApr 2026
NCT04408313NaltrexonePhase 2Opioid-use DisorderPsychiatryMay 2026
NCT07269873NaltrexonePhase 1Healthy Adult Male and Female VolunteersOtherDec 2026
NCT04649892NaltrexonePhase 2Gaming DisorderOtherDec 2026
NCT04678895NaltrexonePhase 2Painful Diabetic NeuropathyNeurologyDec 2026
NCT04464980NaltrexonePhase 2Opioid Use Disorder (OUD)PsychiatryDec 2026
NCT06233799NaltrexonePhase 3Methamphetamine-dependencePsychiatryApr 2027
NCT06620523Glutathione (GSH)Phase 2Renal FailureCardiovascularJun 2027
NCT05537935NaltrexonePhase 4Human Immunodeficiency VirusInfectious diseaseJun 2027
NCT05968690NaltrexonePhase 1Advanced MelanomaOncologySep 2027
NCT06845124NaltrexonePhase 2Alcohol AddictionPsychiatryApr 2028
NCT06620562NaltrexonePhase 4Obesity; DrugMetabolic and endocrineJun 2028
NCT05827159NaltrexonePhase 3Alcohol Use DisorderPsychiatryAug 2028
NCT05827159NaltrexonePhase 3Alcohol Use DisorderPsychiatryAug 2028
NCT06426303NaltrexonePhase 4Alcohol Use DisorderPsychiatryDec 2028
NCT07224009NaltrexonePhase 2Metastatic Prostate CancerOncologyJan 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FKBP1A (1) OPRK1 (1) OPRD1 (1) OPRM1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals ReacX Pharmaceuticals Akyso Therapeutics Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Eisai CSPC ZhongQi Pharmaceutical Technology

Companies built like this

Adneuris Therapeutics HTA Trevi Therapeutics Palvella Therapeutics Acer Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.